2024-03-21 15:30:00 ET
Summary
- Walgreens Boots Alliance, Inc. faces challenges in its retail pharmacy business due to lower demand for COVID-19 testing and tight prescription drug payouts.
- The company is transitioning into a healthcare powerhouse, investing in primary care practices and offering in-home health services.
- Despite declining earnings and cash flow, there is potential for a rebound as Walgreens stock is undervalued and sales are growing in the healthcare division.
Investment Thesis
The challenges for retail pharmacy giant Walgreens Boots Alliance, Inc. ( WBA ) are profound, with lower demand from consumers seeking vaccinations and testing for COVID-19 on one hand and tight reins on prescription drug payouts hobbling its operations. But most crucially, the company's assertive push into other healthcare businesses faces a few sticking points that show catching up might take some time.
Over the past three years, Walgreens has lost nearly 60% in market value as investors reacted to the company's struggles to maintain a positive operating margin. Given the deteriorating fundamentals, it is unsurprising that Walgreens stock has been making lower lows in the market....
Read the full article on Seeking Alpha
For further details see:
Walgreens' Strategic Pivot